Topics
High-grade gliomas | Treatment | Targeted therapy | Nivolumab
Home > Publications > Topics > High-grade gliomas > Treatment > Targeted therapy > Nivolumab
Duerinck J, Lescrauwaet L, Dirven
I, Del'haye J, Stevens L, Geeraerts X,
Vaeyens F, Geens W, Brock S,
Vanbinst AM, Everaert H, Caljon B, Bruneau M,
Lebrun L, Salmon I, Kockx M,
Tuyaerts S, Neyns B.
Intracranial
administration of
anti-PD-1
and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies
in
patients
with recurrent high-grade glioma.
Neuro
Oncol. 2024 Oct
16:noae177. doi:
10.1093/neuonc/noae177. PMID:
39406392. Interventional
study. ˍ